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Abstract — Tryptophan (Trp) metabolism and disposition and excitatory and other amino acid
concentrations were determined in alcohol-dependent subjects in relation to the alcohol-withdrawal
syndrome (AWS). Parameters were examined in 12 alcohol-dependent male subjects, undergoing
elective upper digestive tract tumour resection, and 12 age-, gender-, and medication-matched controls
on three occasions: pre-operatively, post-operatively, and immediately before (i.e. within 24 h of) the
appearance of the AWS. No significant differences were observed between controls and alcoholic
subjects on the first or second ot these occasions. On the third occasion, within 24 h of the appearance of
the AWS, alcoholics showed a dramatic elevation (117%) in free serum Trp concentration and a
consequent increase (111%) in the ratio of [free Trp]/[competing ammo acids], which is an accurate
predictor of Trp entry into the brain. Increases were also observed on this third occasion in
concentrations of total Trp (49%), cortisol (123%), and norharman (137%). Concentrations of glutamate,
glycine, aspartate, serine, and taurine did not differ significantly within or between the control and
alcohol-dependent groups of subjects on any of the three occasions. The possible significance of the Trp
and related metabolic changes in relation to the behavioural features of the AWS is discussed.
INTRODUCTION (GABA)ergic, cholinergic, dopaminergic, nor-
adrenergic, and serotonergic mechanisms (for
The alcohol-withdrawal syndrome (AWS) occurs references, see Stuppaeck et al., 1990). Animal
during the period immediately following cessation studies have, however, suggested that convulsions
of alcohol intake after long-term and heavy and the other severe symptoms of hyperexcit-
consumption by alcohol-dependent subjects, and ability of the AWS may involve activation of the
is characterized by a variety of behavioural excitatory /V-methyl-D-aspartate (NMDA)-type of
disturbances, ranging from symptoms of mild glutamate receptors as an adaptive response to
anxiety and of sympathetic and autonomic activa- withdrawal of ethanol after its long-term con-
tion to convulsions and, in some cases, the more sumption (for reviews, see Gonzales, 1990;
severe state of delirium tremens (Victor and Lovinger, 1995).
Adams, 1953; Charness et al., 1989; Schuckit et A number of physiologically occurring sub-
a/., 1995). The biochemical mediators of the stances act as endogenous modulators of NMD A
human AWS remain unknown, despite many receptor function. These include the major exci-
investigations of the roles of y-aminobutyric acid tatory amino acid glutamate and also aspartate and
glycine, as well as a number of tryptophan (Trp)
metabolites of the kynurenine pathway, such as
•Author to whom correspondence should be addressed. the excitotoxic metabolites quinolinic acid and
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TRYPTOPHAN METABOLISM IN ALCOHOLISM 617
kynurenine, which activate these receptors, and
the cytoprotective metabolite kynurenic acid,
which has antagonistic properties (for review,
see Stone, 1993). These Tip metabolites are
products of the major Trp-oxidative route, the
hepatic kynurenine-nicotinic acid pathway, the
rate-limiting step of which is catalysed by the first
and liver- and L-Trp-specific enzyme, Trp pyrro-
lase (Trp 2,3-dioxygenase, EC 1.13.11.11). These
metabolites are also formed to a lesser extent in
the brain from kynurenine either of peripheral
origin or centrally produced from Trp by the
action of the less substrate- and less tissue-specific
enzyme indoleamine 2,3-dioxygenase (EC
1.13.11.17). Another major difference between
these two enzymes is that, whereas liver Trp
pyrrolase is inducible by glucocorticoids and
activated by its substrate Trp and its co-factor
haem (Badawy and Evans, 1975b), cytokines,
particularly interferon-y, are the principal effectors
of extra-hepatic indoleamine dioxygenase
(Pfefferkorn et al, 1986; Taylor and Feng,
1991). We have previously shown that ethanol
withdrawal enhances liver Trp pyrrolase activity
(Badawy and Evans, 1973, 1975a) and that a
dramatic activation of this enzyme associated
with increased expression of its mRNA occurs in
conjunction with the AWS (Bano et al., 1996) in
rats.
As a first step in studying the possible role of
excitatory amino acids and neuroactive Trp
metabolites in the human AWS, we have
performed a preliminary study in which we
compared a small group of alcohol-dependent
subjects with a matched control group for possible
differences in availability to the brain of the
excitatory amino acids glutamate, aspartate, and
glycine, and of the amino acid Trp (the precursor
of the above neuroactive metabolites) and its
disposition before the appearance of symptoms of
the AWS. Preliminary accounts of parts of this
work have appeared in abstract forms (Badawy et
al., 1996; Bradley et al., 1998).
SUBJECTS AND METHODS
This prospective randomized study was per-
formed on patients at the Department of Anaes-
thesiology and Operative Intensive Medicine of
the Benjamin Franklin Medical Centre, Berlin,
Germany, from whom written informed consent
was obtained, and was approved by the local
Ethics Committee.
Recruitment of patients
Of 106 male patients with a malignant tumour
of the upper digestive tract evaluated, 48 were
diagnosed as alcohol-dependent, using DSM-IV
criteria (American Psychiatric Association, 1994).
Of these 48, 27 elected to receive pharmacopro-
phylactic therapy for alcohol withdrawal (cloni-
dine and flunitrazepam) and were accordingly
excluded. Of the remaining 21 alcohol-dependent
patients, the 12 who developed the AWS after
their post-operative admission to the Intensive
Care Unit (ICU) were included in the study, and
were matched for basic characteristics (age, body
weight, and height), medical condition (cancer
diagnosis), and medication with 12 males admitted
to the ICU, who acted as the control group. With
regard to medication, all subjects (alcohol-depen-
dent and control) received, on the eve of their
operations, flunitrazepam (0.027-0.052 |ig/kg
body wt per os); midazolam (0.19-0.25 ng/kg
body wt per os) was given 1 h pre-operatively, and
peri-operative prophylaxis was with the antibiotics
mezlocillin or cefotiam and metronidazole. Anaes-
thesia was induced with i.v. fentanyl, propofol,
and vecuronium and maintained with the same
three drugs in addition to N2O/O2 (70%: 30%).
Additionally, ranitidine was given to all patients
on the eve of their admission to the ICU. The
alcohol-dependent subjects were also each given a
100-mg dose of vitamin B| daily i.v. Exclusion
criteria were female gender, an age of < 18 years,
diagnosis of liver cirrhosis, and presence of
hepatitis B or C through Child's titre screening.
Diagnostic criteria of alcohol dependence and
assessment of the A WS
As stated above, alcohol dependence was
diagnosed in accordance with the DSM-IV criteria
of the American Psychiatric Association (1994),
including a daily alcohol consumption of >60g,
and also the CAGE questionnaire (Ewing, 1984).
Subjects in the control group had no previous
history of alcoholism, their daily alcohol con-
sumption did not exceed 25 g and their CAGE
questionnaire score was 0. The AWS was
confirmed by a symptom check-list of a diagnostic
schematic instrument based on internationally
accepted algorithms and used routinely by us
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618 A. A.-B. BADAWY et al.
(Heil et al., 1992), and quantified using the
CIWA-Ar scale (Sullivan et al., 1989). Therapy
of the AWS, commenced after the final venesec-
tions (see below), was with flunitrazepam, the
dose of which was titrated until the CIWA-Ar
score dropped below 20. If this was not possible
with the maximum dose of 16 mg, haloperidol
and/or clonidine were also given depending on
whether patients developed vegetative, hallucina-
tory or both symptoms.
Study design
All patients (control and alcohol-dependent
subjects) underwent a comprehensive evaluation
upon admission to the surgical ward, which
included assessment of alcohol dependence and
the related laboratory parameters carbohydrate-
deficient transferrin (CDT), y-glutamyltransferase
(GGT), and mean corpuscular volume (MCV).
Overnight-fasting venous blood samples (25 ml
each) were taken between 08:00 and 09:00 from
all subjects on three occasions: (1) pre-opera-
tively, 24 h before induction of anaesthesia prior
to surgery; (2) post-operatively, on the morning
after the operation; (3) within 24 h before the
appearance of symptoms of the AWS in alcoholic
patients and at the corresponding times for each
matched control. Symptoms of the AWS in
alcohol-dependent patients appeared immediately
upon admission to the ICU (i.e. within 24 h of
surgery) in two subjects, within 2 days of this
admission in two other subjects, within 3 days in
four subjects, and within 4 and 5 days in two
subjects each. The AWS therefore took an average
of 2.8 ± 0.5 days (mean ± SEM), with a median of
3 days, to appear in this group of patients.
Accordingly, to obtain the blood sample immedi-
ately preceding the appearance of the AWS, daily
venesections were made up until observation of
the AWS. These intermediate samples were,
however, not analysed.
Laboratory investigations
Serum CDT was determined by a research
procedure based on micro-anion-exchange chro-
matography and subsequent turbidometry as
described previously (Muller et al., 1993) in
which a CDT level above 9 mg/1 is considered
pathological (Heil et al., 1994), whereas GGT and
MCV were determined by standard clinical
laboratory procedures, in which the normal ranges
for German laboratories are 6-28 U/l and 80-96 fl
respectively. Serum cortisol concentration was
determined by an ELISA immunoassay, whereas
those of amino acids were determined by the
autoanalyser procedure. Free (ultrafiltrable) and
total (free + albumin-bound) serum Trp concen-
trations were determined fluorimetrically by a
modification (Bloxam and Warren, 1974) of the
method of Denckla and Dewey (1967), as
described previously (Badawy and Evans, 1976).
Ultrafiltration of serum was performed on fresh
(unfrozen) samples within 2 h of isolation, to
avoid the effect of frozen storage on Trp binding
(Morgan and Badawy, 1994), using the Amicon
micropartition MPS-1 assembly (Amicon GmbH,
Witten, Germany) and after centrifugation of 1-ml
portions of serum at room temperature at 2000 g
for 20 min. Trp binding was expressed as the
percentage free serum Trp (100 x [free serum
Trp]/[total serum Trp]). Concentrations of the
physiological binder of Trp, namely albumin
(Doumas and Biggs, 1972), and displacers of
albumin-bound Trp, namely non-esterified fatty
acids (NEFA) (Mikac-Devic et al., 1973) and
those of glucose (Slein, 1963) and the major
Trp-oxidation product kynurenine (Joseph and
Risby, 1975) were determined by standard proce-
dures. Norharman concentration was determined
in plasma samples by high-performance liquid
chromatography and fluorimetric detection as
described previously (Spies et al., 1995).
Statistical analysis of results
Intergroup differences between numerical vari-
ables were analysed by means of the Wilcoxon
rank-sum test for unrelated variables. Differences
between groups for dichotomous variables were
analysed by the #2-test. For intra-group analyses,
the Friedman test was used for global differences.
All statistical analyses were performed using the
PC version of the Statistical Package for the Social
Sciences (SPSS for Windows, Chicago, USA).
RESULTS
Patient group diagnostic characteristics
The results in Table 1 show that the control and
alcohol-dependent patient groups did not differ
significantly in age. By contrast, the alcoholic
group had a CAGE score for alcohol-dependence
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The above parameters were determined as described in
the Subjects and methods section. Values are means
± SEM for each group of 12 subjects. *The signifi-
cance of the differences between the control and al-
cohol-dependent subject groups (/>) has been calculated
using the Wilcoxon exact two-tailed test. For carbohy-
drate-deficient transferrin (CDT). the pathological cut-
off point for the research method used is 9 mg/1,
whereas the normal ranges for the routine clinical
laboratory procedures used for determination of y-glu-
tamyl transferase (GGT) and mean corpuscular volume
(MCV) in German laboratories are 6—28 U/l and
80-96 fl respectively.
diagnosis of 3.4 ±0.1 (mean ± SEM) against a
score of 0 for the control group, and a CIWA-Ar
score for severity of withdrawal assessment of
32.5 ± 3.1 against a low score for controls of
9.3 ± 1.8. Alcoholics also had CDT values much
higher than those of controls, which were below
the pathological level of 9 mg/1. GGT and MCV
values were also raised in alcoholics, but not in
controls, as would be expected in a diagnosis of
alcohol dependence.
Comparison of parameters ofTrp metabolism
and disposition in alcoholics and controls
These parameters were examined on three
occasions in the two groups of patients, namely
pre-operatively, post-operatively and immediately
before (i.e. within 24 h of) the appearance of the
AWS (or the corresponding times for matched
controls). The results in Table 2 show that there
were no significant differences in free serum or
total serum Trp concentrations or Trp binding to
albumin (expressed as the percentage free serum



























































































































































Experimental details are as described in the Subjects and methods section. Values are expressed as ratios or in ug/ml.
except for the |CAA|, which is in uM, and are means ± SEM for each group of 12 subjects. The significance of the
differences between the control and alcohol-dependent groups, given as exact two-tailed P, which were compared
using the Mann-Whitney U test, is as follows: *P < 0.0145; *P < 0.0034: **P < 0 002: ***P < 0.0000. Abbrevia-
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The above parameters were determined in serum (except norharman, which was determined in plasma) as described in
the Subjects and methods section, and are expressed as follows: albumin (g/1), NEFA (mM), glucose (mg/dl), cortisol
(nM), and norharman (pg/ml). Values are means ± SEM for each group of 12 subjects. The significance of the differ-
ences between the alcohol-dependent and control subjects at the relevant occasions shown is indicated as follows:
*P < 0.0387; **P < 0.0029; ***P < 0.0014 (Mann-Whitney U exact two-tailed test). Abbreviations used: NEFA,
non-esterified fatty acids; AWS, alcohol-withdrawal syndrome; Trp, tryptophan.
Trp) between the control and alcohol-dependent
patient groups on the first of the above occasions.
On the second occasion, both free and total serum
[Trp] were respectively 28% and 16% higher in
the alcohol-dependent group; however, these
increases did not reach statistical significance.
Trp binding (expressed as above) also remained
unaltered on this second occasion. On the third
occasion, shortly before the appearance of the
AWS, free serum [Trp] was dramatically elevated,
by 117%, with total serum [Trp] also rising by
49% in comparison with the corresponding values
in the control group (P = 0.0145 at least). Because
of the greater rise in free, compared to total, serum
[Trp] on this occasion, the percentage free serum
Trp was significantly increased in the alcohol-
dependent group, by 57% (P < 0.002). The results
in Table 2 also show that the serum concentration
of the major Trp-oxidative product kynurenine
was not significantly different between the control
and alcohol-dependent subjects, though a trend
towards an increase was observed in the third
sample of the latter subjects. Trp availability to the
brain, expressed as the [Trp]/[CAA] ratio was also
assessed. As the data in Table 2 show, the [free
Trp]/[CAA] ratio was not significantly different
between controls and alcohol-dependent patients
on the first or second occasion, although on the
latter occasion there was a trend towards an
increase in the alcoholic group. On the third
occasion, i.e. within 24 h of the appearance of the
AWS, the [free Trp]/[CAA] ratio was dramatically
increased in the alcohol-dependent, to 111%
above the corresponding value in the control,
subjects (P < 0.0000). By contrast, there were no
significant within- or between-group differences
in the [total Trp]/[CAA] ratio, although a trend
towards an increase was observed on the third
occasion in the alcohol-dependent group. The
above increase in the [free Trp]/[CAA] ratio on
the third occasion was due to the dramatic increase
in [free Trp] and not any likely decrease in the
sum of [CAA], which was in fact higher in the
alcohol-dependent patients than in the control
subjects, though the difference was not statisti-
cally significant.
Comparison of parameters related to Trp
metabolism and disposition in alcoholics and
controls
The results in Table 3 show such comparisons.
There were no significant between- or within-
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Concentrations of the above amino acids were determined in sera as described in the Subjects and methods section. Va-
lues are means ± SEM for each group of 12 subjects. No significant within- or between-group differences were ob-
served at any of the above three time intervals. Abbreviation used: AWS, alcohol-withdrawal syndrome.
group differences in concentrations of the physio-
logical binder of Trp (albumin), displacers of
albumin-bound Trp (NEFA), or glucose (changes
in levels of which can trigger an insulin-mediated
modulation of Trp entry into the brain) at any of
the three time intervals tested. By contrast,
concentration of cortisol (the major glucocorticoid
inducer of human liver Trp pyrrolase) was
increased in the alcohol-dependent, but not the
control, group by 124 and 207% on the second and
third sampling occasions respectively, in compar-
ison with the value on the first occasion (P < 0.02,
by Student's /-test). In comparison with the
control group, the alcohol-dependent patient
group showed a dramatic increase in cortisol
concentration on the third occasion (124%;
P < 0.0029). Plasma norharman (/?-carboline), a
complex metabolite of indolylamines of interest-
ing pharmacological properties, was also higher in
the alcohol-dependent patients, compared with
controls, on the first and third sampling occasions
(by 122 and 137% respectively; P = 0.0387-0.0014,
Mann-Whitney U exact two-tailed test).
Comparison of excitatory and other amino acid
concentrations in alcoholics and controls
The results in Table 4 show that the serum
concentrations of the excitatory amino acids
glutamate, glycine, and aspartate, and also those
of serine and taurine did not differ significantly
between controls and alcohol-dependent subjects,
nor within each group, at any of the three time
intervals at which they were examined.
DISCUSSION
Current views suggest that the behavioural
features of the AWS may involve hyperexcit-
ability resulting from modulation of function of
the NMDA-type of glutamate receptors. Although
evidence in support of this concept has been
obtained from animal studies (for reviews, see
Gonzales, 1990; Lovinger, 1995), no evidence has
as yet emerged to implicate NMDA receptor
function modulation in the human AWS. In the
present study, we have attempted to address this
question in alcohol-dependent patients by exam-
ining the availability to the brain of endogenous
modulators of NMDA receptor function shortly
before (within 24 h of) the appearance of the
AWS. No increase in the availability in the
circulation of the major excitatory amino acid
glutamate, the other excitatory amino acids
aspartate and glycine, or the other neuroactive
amino acids serine and taurine was observed
(Table 4). These results therefore strongly suggest
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622 A. A.-B. BADAWY et al.
that availability to the brain of neuroactive amino
acids of peripheral origin (including the major
NMDA receptor agonist glutamate) is not an
important factor in the development of the human
AWS. Whether such availability may be important
at the time of appearance of the AWS requires a
more detailed and longer time-course study. The
alternative possibility, that of involvement of
intracerebral changes in excitatory and/or other
neuroactive amino acids in the AWS, remains to
be investigated.
Another group of endogenous modulators of
NMDA receptor function are the metabolites of
the kynurenine pathway of Trp degradation,
namely quinolinic acid, kynurenine and kynurenic
acid (for review, see Stone, 1993). Excitotoxic
quinolinate is a powerful agonist of NMDA
receptors, whereas kynurenate exerts a cytopro-
tective influence by virtue of antagonism at these
receptors. Kynurenine is also an NMDA receptor
agonist, though not as strong as its metabolite
quinolinate. The possible involvement of quinoli-
nate as an excitotoxic mediator of the AWS has
been proposed by Morgan (1991) on the basis of
the following previous findings in animals: (1)
increased blood-brain barrier permeability to Trp
after chronic ethanol administration; (2) dramatic
elevation of brain quinolinate levels after acute
Trp loading, even to 200-fold in localized brain
areas; (3) increased circulating levels of Trp
secondary to hepatic dysfunction, which is invari-
ably a feature of long-term and heavy alcohol
consumption; (4) enhancement of liver Trp
pyrrolase activity during alcohol withdrawal and
its possible mediation by glucocorticoids (for
references, see Morgan, 1991).
We have not investigated the quinolinate or
kynurenate status of alcoholic patients in the
present preliminary study, because it was con-
sidered important to establish in the first instance
the status and disposition of their precursor amino
acid Trp, as these are the primary determinants of
synthesis of these neuroactive metabolites. As the
present results show, a dramatic increase (117%)
in free serum [Trp] associated with a significant
increase (49%) in that of total serum Trp were
observed shortly before the appearance of the
AWS in alcohol-dependent men (Table 2). Circu-
lating Trp availability to the brain is determined
by three major peripheral factors: (1) at the
primary level, activity of the major Trp-degrading
enzyme, hepatic Trp pyrrolase, which controls
the quantitatively most important of the Trp-
degradative routes, the hepatic kynurenine-nico-
tinic acid pathway (Badawy, 1977); (2) at the
secondary, but more immediate, level, extent of
protein binding of Trp and hence of its modulation
by the physiological binder albumin and displacers
from the albumin-binding sites' NEFA (Curzon
and Knott, 1974); (3) extent of competition
between Trp and five other circulating amino
acids (Val, Leu, He, Phe, and Tyr), collectively
known as the competing amino acids or CAA, for
the same cerebral uptake mechanism (Fernstrom
and Wurtman, 1971). In human studies of Trp
metabolism and disposition, the most accurate
predictor of Trp entry into the brain is therefore
not serum [Trp] alone, but the ratio of the latter to
the sum of the Trp competitors, i.e. the [Trp]/
[CAA] ratio, and, as the results in Table 2 also
show, the [free serum Trp]/[CAA] ratio was also
dramatically elevated (by 111%) shortly before the
appearance of the AWS, purely because of the
increase in [free serum Trp] and not a decrease in
the [CAA]. This increase in the [free serum Tip]/
[CAA] ratio is almost certain to lead to a large
increase in brain [Trp]. Brain [Trp] is the single
physiologically most important determinant of
cerebral serotonin (5-hydroxytryptamine, 5-HT)
synthesis, because the rate-limiting enzyme of the
5-HT-biosynthetic pathway, Trp hydroxylase, is
unsaturated with its Trp substrate (Fernstrom and
Wurtman, 1971; Carlsson and Lindqvist, 1978;
Curzon, 1979). The increase in circulating Trp
availability to the brain shortly before the
appearance of the AWS observed in the present
work is therefore almost certain to lead to an
increase in brain serotonin synthesis. Although the
behavioural effects of serotonin excess are well
known, their possible involvement in the human
acute AWS has not previously been suggested and
may merit investigation. An increase in brain
[Tip] shortly before the appearance of the above
syndrome, as suggested by the results in Table 2 of
the present work, could also lead to increased
production of the excitotoxic NMDA receptor
agonist quinolinic acid, possibly in large amounts
in certain brain areas, as mentioned above
(Morgan, 1991). The likelihood of this possibility,
however, depends on whether brain indoleamine
dioxygenase is active enough under these condi-
tions to convert Trp into adequate amounts of
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quinolinate. Although brain indoleamine dioxy-
genase could not be examined directly in alcoholic
patients, an indirect indicator of its activity is the
level of serum (or urinary) neopterin (see Fuchs et
al., 1996 and references cited therein), measure-
ment of which may therefore be necessary in
studying the above possibility. As stated in the
Introduction, the principal effector of indoleamine
dioxygenase is interferon-y and activity of this
enzyme is induced dramatically under conditions
of immune activation (see Pfefferkorn et al., 1986;
Taylor and Feng, 1991). Neither the immune
status of alcohol-dependent humans during acute
withdrawal nor the effect of withdrawal on
indoleamine dioxygenase activity in animals are
known, but it is tempting to speculate that, should
the immune status be shown to be enhanced, the
resulting induction of indoleamine dioxygenase, in
conjunction with increased entry of Trp into the
brain, could provide the optimum conditions for
enhanced intracerebral synthesis of quinolinic
acid.
The mechanisms by which the 117% increase in
[free serum Trp] and the 49% increase in [total
serum Trp] (Table 2) occur shortly before the
appearance of the AWS are not fully understood at
present. As regards the large increase in [free
serum Trp], NEFA could not be held responsible,
since their levels were not altered (Table 3). By
contrast, serum [albumin] was decreased by 16%
(P < 0.005 by Student's r-test) in the alcohol-
dependent patients on the third occasion, in
comparison with the value on the first occasion.
We have previously shown (Badawy et al., 1985)
that a 16% decrease in serum [albumin] (during
late pregnancy in rats) is the threshold value at
which Trp binding to albumin becomes signifi-
cantly decreased. It may therefore be concluded
that part of the above increase in [free serum Trp]
is due to decreased albumin binding (as also
suggested by the associated significant increase in
the percentage free serum Trp). As regards the
49% increase in [total serum Trp], inhibition of
liver Trp pyrrolase activity is usually the main
cause of elevation of total serum Trp, which in a
typical case is also accompanied by a similar
increase in [free serum Trp] (see, e.g. Badawy et
al., 1985). The only other likely explanation of the
increase in [total serum Trp] is that of release from
protein breakdown. This possibility is, however,
unlikely in view of the fact that levels of other
amino acids (e.g. the Trp competitors or excitatory
amino acids) were not elevated (Tables 2 and 4). It
may therefore be concluded that the increases in
circulating [Trp] observed in the present work may
be caused by decreased albumin binding and
inhibition of liver Trp pyrrolase activity. The
mechanism of such a possible inhibition is not
understood, but one possibility is that of mediation
by norharman [a known inhibitor of Trp pyrrolase
activity (Eguchi et al., 1984)], whose circulating
concentration was also dramatically increased in
alcoholics on the third occasion (Table 3), and
possibly also by catecholamines (Satoh and Moroi,
1969), whose circulating levels are usually also
increased during alcohol withdrawal.
If liver Trp pyrrolase activity is inhibited shortly
before the appearance of the AWS, as the present
results suggest, a strong possibility that it will
become subsequently enhanced is indicated by the
dramatic elevation of serum [cortisol] (Table 3).
This hormone is the major glucocorticoid inducer
of human liver Trp pyrrolase and an elevation of
its circulating concentration of the magnitude
observed in the present work is almost certain to
herald pyrrolase induction. If such induction were
to occur on subsequent days, one would expect
levels of Trp to decrease and those of the major
oxidative product kynurenine to rise. As the
results in Table 2 show, a trend towards
kynurenine elevation in the alcohol-dependent
subjects was already apparent on the third
occasion. A longer time-course study will there-
fore be required to examine these additional
aspects of Trp disposition. It is tempting to
speculate here, however, that the cortisol elevation
observed in the present work, which is a well
known feature of acute alcohol withdrawal (see,
e.g. Adinoff et al., 1991) may help to accelerate
hepatic Trp degradation to decrease its availability
to the brain for quinolinate synthesis. Another
potential mechanism of inhibition of this synthesis
is that involving norharman, a known inhibitor of
indoleamine dioxygenase activity (Eguchi et al.,
1984), an increase in the circulating concentration
of which was also observed in the present work
(Table 3), as well as previously by us in other
alcohol-dependent subjects (Spies et al., 1995).
The absence of a significant change in serum
kynurenine concentration observed in the present
work (Table 2) deserves further comment. An
increase in serum kynurenine concentration in the
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presence of a rise in that of Tip usually reflects
increased flux of the amino acid through its
oxidative pathway without a net change in Tip
pyrrolase activity (e.g. after a small Tip-loading
dose), whereas activation of Tip pyrrolase leads to
an increase in serum kynurenine concentration and
a decrease in that of Tip. The finding (Table 2)
that serum kynurenine concentration was only
slightly increased on the third sampling occasion
when serum [Trp] was dramatically elevated
suggests that either an increase in circulating
kynurenine concentration may follow shortly
afterwards or that flux of Trp through its oxidative
pathway is impaired at this time, because of a
possible pyrrolase inhibition as stated above. A
longer time-course study of Trp disposition and
metabolism should establish a clearer picture of
the Trp metabolic status in alcohol withdrawal.
In conclusion, we have explored in the present
work the availability to the brain of some
endogenous modulators of NMDA receptor func-
tion in relation to the AWS in alcohol-dependent
men. Our results show that, whereas availability of
excitatory and other neuroactive amino acids to
the brain is not increased, that of Trp is. Trp is the
precursor of an important group of neuroactive
metabolites known to modulate NMDA receptor
function and to influence mood and behaviour,
and the changes in its availability and disposition
observed in the present work justify a detailed
investigation of its metabolism and role in
determining cerebral levels of the neuroactive
metabolites quinolinate and kynurenate in relation
to alcohol dependence.
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